U.S. Marine and Shipping Stock News

NYSE:HAE
NYSE:HAEMedical Equipment

Haemonetics (HAE) Could Be 10% Undervalued On Its Margin Expansion Story

Haemonetics (HAE) has drawn attention after recent share price moves, including a gain of about 7% over the past month and roughly 26% over the past 3 months. These changes are prompting closer examination of its fundamentals. See our latest analysis for Haemonetics. At a share price of $77.86, Haemonetics shows recent momentum with a 30 day share price return of 7.05% and a 90 day share price return of 26.36%. This is set against a more modest 1 year total shareholder return of 7.32% and a 3...
NasdaqGS:SOFI
NasdaqGS:SOFIConsumer Finance

SoFi (SOFI) Stock Looks Overvalued At Today’s Price

SoFi Technologies stock has delivered an 83.2% gain over the past three years, yet the latest valuation work suggests the shares trade at a premium, with both the intrinsic value estimate from the Excess Returns model and the market multiples pointing to overvaluation. The 83.2% return over three years puts SoFi in the category of stocks that have already rewarded shareholders. This can leave less room for error if expectations change. Growth in SoFi's banking and broader financial services...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival

Partner trial for Darzalex Faspro using Halozyme's ENHANZE technology reported significant survival benefits for multiple myeloma patients. Late stage study results point to improved outcomes for people receiving this subcutaneous therapy. News is material for Halozyme Therapeutics (NasdaqGS:HALO) as it relates directly to one of its key partnered medicines. Halozyme Therapeutics centers its business on ENHANZE, a drug delivery technology licensed to large biopharma partners. The latest...
NYSE:HXL
NYSE:HXLAerospace & Defense

Hexcel (HXL) Heads To Farnborough, Is The Stock Already Pricey?

Hexcel (HXL) stock is drawing fresh attention after the company confirmed it will showcase its latest high performance composite materials and pursue new industry partnerships at the 2026 Farnborough International Airshow. See our latest analysis for Hexcel. The Farnborough announcement comes after a strong run in Hexcel’s stock, with a 16.96% 90 day share price return and a 73.23% 1 year total shareholder return signalling building momentum at the current US$103.81 share price. If Hexcel’s...
NasdaqGS:ACGL
NasdaqGS:ACGLInsurance

Arch Capital Group (ACGL) Jumps 10% In A Month, Is It Still 8% Undervalued?

Arch Capital Group (ACGL) has caught investors’ attention after a 9.7% stock return over the past month, coinciding with updated earnings estimates that point to a 5% year-over-year decline this quarter. See our latest analysis for Arch Capital Group. Looking beyond the past month, Arch Capital Group’s 1 year total shareholder return of 14.71% and 5 year total shareholder return of 176.62% sit alongside a 7.98% year to date share price return. This suggests momentum has been building despite...
NasdaqGS:VC
NasdaqGS:VCAuto Components

Visteon (VC) Secures Multi Year Memory Supply Deals For AI Ready Vehicles

Visteon (NasdaqGS:VC) has entered new multi year partnership agreements to secure advanced memory and storage supplies for automotive applications. The company is part of Micron's newly completed Strategic Customer Agreements alongside other major automotive suppliers and partners. The partnerships focus on long term supply and technology planning for next generation, AI enabled vehicle platforms. Visteon sits at the intersection of automotive electronics and software, supplying cockpit...
NYSE:CLX
NYSE:CLXHousehold Products

Clorox (CLX) Stock May Be 35% Undervalued As Earnings Near

After several years where Clorox stock has fallen about 38% over 5 years, current valuation checks point in the opposite direction, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples suggesting the shares may now be pricing in relatively low expectations. The share price decline of roughly 38.2% over 5 years signals that investors have been marking Clorox down, even before considering today’s valuation signals. Expectations for pressured margins and softer...
NYSE:MP
NYSE:MPMetals and Mining

Rare Earth Stocks To Watch As Magnet Supply Security Gains Importance

Rare earth metal stocks sit at the crossroads of technology, defense, and the clean energy buildout. Today’s mixed global backdrop, from steady US bond yields to shifting industrial output in Asia and Europe, keeps attention firmly on supply security for these materials. With only a limited pool of companies focused on mining these critical elements, a targeted Rare Earth Metal Stocks screener can help you cut through market noise and focus on pure exposure to this theme. This article...
NYSE:RTX
NYSE:RTXAerospace & Defense

Will RTX’s (RTX) £2 Billion UK Army Training Win Recast Its Defense Tech Narrative?

Earlier this month, the UK Ministry of Defence awarded Omnia Training a £2.00 billion, 15-year contract to become the British Army’s Strategic Training Partner, with a RaytheonUK-led consortium delivering a digitally enabled collective training system that blends virtual, synthetic and data-driven environments. This win underlines RTX’s deepening role in high-tech military training and synthetic environments, reinforcing its broader push into advanced defence technologies and integrated...
NasdaqGS:NTRA
NasdaqGS:NTRABiotechs

Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued

Natera (NTRA) stock is in focus after two key developments: a final local coverage determination expanding Prospera transplant test access and stronger than expected revenue growth supported by higher testing volumes. See our latest analysis for Natera. Natera’s recent developments appear to be reflected in its share price, with a 30.2% 90 day share price return and a very large 3 year total shareholder return that suggests momentum has been building over a longer period. If Natera’s move has...
NYSE:ES
NYSE:ESElectric Utilities

Is Eversource Energy (ES) Fairly Valued As Regulatory Progress Supports Its Outlook?

How Eversource Energy Stock Has Been Performing Eversource Energy (ES) has been trading without a clear single news catalyst, so investors are focusing on how the stock has moved recently and how that lines up with its fundamentals. Over the past month, the stock has gained about 8%, and over the past 3 months it is up roughly 7.8%. Year to date, Eversource Energy shows a total return close to 9.6%, with the 1 year total return around 19.3%. On a longer view, the 3 year total return stands...
NasdaqGS:ETOR
NasdaqGS:ETORCapital Markets

eToro (ETOR) Stock Looks Like A Bargain On Earnings Yet Full On Fair Value

eToro Group stock has fallen 36.6% over the past year, yet the latest valuation checks are split, with the Excess Returns intrinsic value estimate pointing to a premium while market based multiples still screen the shares as relatively cheap. That tension between a weak share price track record and conflicting valuation signals is what investors are trying to make sense of today. Over the last 12 months, eToro Group is down 36.6%, which puts recent enthusiasm around the stock against a still...
NYSE:GBX
NYSE:GBXMachinery

Greenbrier (GBX) Stock Still Looks Like A Bargain Despite 37% Run

Greenbrier Companies stock has delivered a 37.0% total return over the past 5 years, yet the latest valuation checks point to a mixed picture rather than a clear bargain or clear premium at the current US$50.02 share price. Over 5 years, a 37.0% return suggests Greenbrier Companies has rewarded patient shareholders, which naturally raises the bar for fresh upside from here. Future demand for railcars and related services can support earnings and cash flow, while any pressure on manufacturing...
NYSE:SMG
NYSE:SMGChemicals

Is Scotts Miracle-Gro (SMG) Refocus on U.S. Consumer Poised to Reshape Its Investment Narrative?

Earlier this week, Scotts Miracle-Gro reported that strong demand in its core U.S. Consumer segment coincided with progress on innovation, acquisitions, cost-saving measures, and supply chain enhancements, alongside the divestiture of its Hawthorne business to streamline operations. This combination of refocusing on the core consumer franchise and exiting Hawthorne is drawing attention to how a leaner structure could affect earnings quality and operational consistency. Now, we’ll explore how...
NYSE:CIEN
NYSE:CIENCommunications

Is Ciena (CIEN) Priced For Growth Or Cash Flow Value?

Ciena stock has delivered a very large three year gain of roughly 7.8x, yet the company now sits in an unusual valuation split where the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while earnings based multiples suggest the shares are expensive compared with peers. Over the past three years, Ciena has returned roughly 7.8x, so the current debate centers on how much of the company’s potential is already reflected in the price. Progress in quantum safe data...
NasdaqGS:ACIW
NasdaqGS:ACIWSoftware

ACI Worldwide (ACIW) Stock Looks Cheap On Cash Flow While Earnings Look Fair

ACI Worldwide stock has surged over the past three years, yet the valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below that estimate while the broader checks still do not flag the stock as a clear bargain. ACI Worldwide has returned 150.3% over the past three years, which puts extra focus on whether the current price still leaves room above intrinsic value or mainly reflects past gains. Recent news...
NYSE:GM
NYSE:GMAuto

General Motors Stock And 2 US Auto Makers Built For Tariff Pressure

The tariff clock is ticking for U.S. auto manufacturers, and the expiry of President Trump's temporary 10% global tariff has put fresh attention on which stocks may be positioned to cope with the next round of trade policy changes. With new, potentially more permanent duties on the horizon, investors are reassessing how global supply chains, import exposure, and cost structures could affect returns. This article walks through three stocks from a U.S. domestic auto manufacturers screener that...
NYSE:BNY
NYSE:BNYCapital Markets

BNY (BNY) Stock Could Be 15% Overvalued Despite Record Earnings

After a very strong three year share price run of 277.6%, Bank of New York Mellon Corporation now faces a valuation debate, with its intrinsic value estimate from the Excess Returns model pointing to the stock trading at a premium, while market multiples suggest pricing that is closer to about right. BNY has delivered a very large 277.6% total return over three years, which means a lot of optimism is already reflected in the share price. Recent earnings momentum, supported by fees, interest...
NasdaqGS:MPWR
NasdaqGS:MPWRSemiconductor

Monolithic Power Systems (MPWR) Stock Looks Stretched Following Its 228% Five Year Run

Monolithic Power Systems stock has delivered very strong gains over the past few years, yet the latest valuation checks suggest the shares now lean expensive rather than like a clear bargain. Over the last 5 years, Monolithic Power Systems has returned 228.4%, which puts recent share price weakness into context as a pullback after a long period of strong compounding. Expectations around AI related demand in data and communications can support a rich valuation, while ongoing legal and...
NYSE:FIX
NYSE:FIXConstruction

Comfort Systems USA (FIX) Stock May Trade At A 36% Discount After AI Infrastructure News

Comfort Systems USA has been on a remarkable run over the past few years, yet at around US$1,674 per share the stock still screens as undervalued on both an intrinsic value estimate using a Discounted Cash Flow (DCF) approach and on market multiples. That sets up a clear tension for investors, with very strong long term returns on one side and valuation tools suggesting the current price may still sit below intrinsic value. Over the past 5 years, Comfort Systems USA has delivered a very...
NasdaqGS:OUST
NasdaqGS:OUSTElectronic

Ouster (OUST) Updates EBITDA Breakeven Plan On A Valuation Narrative Still In Question

Ouster (OUST) recently updated investors on its financial roadmap, highlighting a focus on reaching EBITDA breakeven supported by efforts in revenue growth, product development across its lidar portfolio, and wider adoption in automotive, industrial, and smart infrastructure markets. See our latest analysis for Ouster. The recent EBITDA breakeven update comes after a mixed share price run, with Ouster’s 1 day share price return of 5.41% contrasting with a 7 day decline of 14.42%, a 30 day...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

Is CrowdStrike (CRWD) Using EU-Sovereign AI Security Deals To Recast Its Competitive Identity Moat?

CrowdStrike and Schwarz Digits recently expanded their partnership to deliver the AI-native Falcon cybersecurity platform on STACKIT, a sovereign EU cloud, while CrowdStrike also agreed to acquire XM Cyber’s intellectual property and appointed former Splunk Security executive AJ Shipley as Chief Product Officer. These moves, alongside Frost & Sullivan naming CrowdStrike the 2026 Global Company of the Year in Identity Threat Detection and Response, highlight the company’s push to anchor...
NasdaqCM:ESQ
NasdaqCM:ESQBanks

Is Esquire Financial (ESQ) Pre‑Earnings Trading Hinting At A Shift In Its Growth Narrative?

Earlier this week, Esquire Financial Holdings saw heightened trading activity as investors focused on its upcoming second-quarter earnings release and anticipated year-over-year growth in earnings and revenue. The unchanged consensus EPS estimate over the past month, despite this optimism, suggests analysts are waiting for actual results before revising their expectations. Next, we’ll explore how this pre-earnings optimism, reflected in stronger trading interest, could influence Esquire...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Does Moderna’s (MRNA) New mRNA-4200 Trial Quietly Rebalance Its Long-Term Oncology Risk Profile?

Earlier this month, Moderna announced it had dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an mRNA-based, tumor-targeted cancer antigen therapy being tested with checkpoint inhibitor treatment in adults with advanced solid tumors under its collaboration with Immatics. This early-stage oncology milestone underscores Moderna’s effort to extend its mRNA platform beyond infectious diseases into cancer, adding a new dimension to how investors may think about the company’s...